Other reports hypothesized that ACE inhibitors and nicotine exposure may be associated with cardiorespiratory manifestations in COVID-19 due to upregulation of ACE-2 receptors (which is essential for SARS-COV-2 cell entry), however this remains to be properly studied [96–98]. Here, ACE is linked to COVID-19.